IMB 2024 Financial Report: Profit Up 4.5%, NGP Revenue Jumps 26%

Nov.19.2024
IMB 2024 Financial Report: Profit Up 4.5%, NGP Revenue Jumps 26%
Imperial Brands released its full-year 2024 financial results, reporting a 0.2% year-on-year decline in total revenue to £32.411 billion, while adjusted operating profit increased by 4.5% year-on-year to £3.887 billion.

On November 19, Imperial Brands (IMB) announced its full-year financial results for the period ending September 30, 2024. The company reported a slight decline in total revenue, which fell by 0.2% year-on-year to £32.411 billion.

 

Despite the dip in revenue, adjusted operating profit rose by 4.5% to £3.887 billion. Adjusted net revenue for the "Tobacco and Next Generation Products (NGP)" segment increased by 4.6%, reaching £8.157 billion.

 

Key highlights of the report:

 

  • Tobacco and NGP net revenue increased by 4.6%.
  • Market share gains were reported in four out of IMB’s five priority markets, with an overall increase of 0.05%.
  • NGP's net revenue grew by 26%, with all three regions achieving growth and improved margins.
  • Logista's growth reflected strong tobacco pricing and benefits from last year’s acquisitions.
  • Adjusted earnings per share (EPS) rose by 10.9%, driven by profit growth and a reduced share count, while reported EPS increased by 19.1%.
  • Strong cash generation, with free cash flow reaching £2.4 billion.
  • IMB plans to return approximately £2.8 billion to shareholders in FY25, including a £1.25 billion share buyback and a 4.5% increase in the FY24 dividend.

 

IMB 2024 Financial Report: Profit Up 4.5%, NGP Revenue Jumps 26%
IMB Full-Year Report to September 30, 2024| Source: IMB official website

 

The report highlights that overall market share in IMB’s five priority markets increased by 5 basis points (bps). Growth was recorded in the U.S., Germany, Spain, and Australia, while the U.K. saw a decline.

 

In Europe, strong growth in tobacco and Next Generation Product (NGP) net revenue was noted, with a stable market share in Germany. In the Americas, the successful launch of the modern oral nicotine brand "Zone" drove a 29.4% increase in NGP net revenue. In Africa, Asia, and the Middle East, effective tobacco pricing strategies contributed to further market share expansion.

 

Notably, NGP's net revenue grew by 26.4%, with all three categories—heated tobacco, vaping, and modern oral —experiencing growth.

 

Stefan Bomhard, CEO of IMB, said:


"As we enter the final year of our current strategy, the investment we have made in consumer capabilities, cultural transformation and agile ways of working has supported another year of accelerated financial delivery and growing capital returns. "

 

"In tobacco, investment in our brands and sales force initiatives have delivered aggregate market share gains across our five priority markets, while delivering strong pricing. This was supported by an encouraging stabilisation in German market share for the first time under our strategy"

 

"In next generation products (NGP), we continue to build scale across our footprint with net revenues up 26.4% at constant currency driven by growth from all three regions and market share growth in all three categories. Our partnership approach to product innovation has enabled us to launch new products across all three categories during the year. This included our successful entry to the fast-growing modern oral category in the US with our brand ‘Zone’."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Philip Morris Japan Unveils TEREA “Blossom Pearl” for IQOS ILUMA
Philip Morris Japan Unveils TEREA “Blossom Pearl” for IQOS ILUMA
Philip Morris Japan announced that it will launch “TEREA Blossom Pearl,” a new tobacco stick for IQOS ILUMA, on May 11. The new product will expand the TEREA lineup to 27 variants. It features a capsule menthol flavor with strawberry and subtle herbal notes and is priced at JPY 620, or about USD 4.14 based on an assumed rate of 1 JPY = 0.00668 USD. The exchange-rate source should be verified and added.
Apr.28 by 2FIRSTS.ai
Kyrgyzstan Plans to Extend E-Cigarette Import Ban by Another Six Months
Kyrgyzstan Plans to Extend E-Cigarette Import Ban by Another Six Months
According to Kyrgyzstan’s Ministry of Economy, the government plans to extend the current ban on e-cigarette imports by another six months once the existing measure expires, with the new restriction set to take effect on July 10, 2026. The ban covers disposable e-cigarettes as well as nicotine-containing liquids for reusable systems.
Apr.17 by 2FIRSTS.ai
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
WHO’s First Global Report on Nicotine Pouches: Harm Reduction Questions Remain Amid Global Regulatory Warning
Ahead of World No Tobacco Day 2026, WHO released its first global report on nicotine pouches, warning that rapid market growth, youth-oriented marketing and weak regulation are converging. 2Firsts views the report as an important warning, but not a complete risk assessment, with harm-reduction questions still unresolved.
Special Report
May.17
Al Fakher Enters the Oral Nicotine Market With Four Flavors
Al Fakher Enters the Oral Nicotine Market With Four Flavors
Al Fakher has launched nicotine pouches, marking the world’s leading hookah brand’s entry into the modern oral nicotine category.
Apr.01 by 2FIRSTS.ai
Thai Vape User Numbers Rose More Than 11-Fold in Three Years, Group Says Ban Should Be Reassessed
Thai Vape User Numbers Rose More Than 11-Fold in Three Years, Group Says Ban Should Be Reassessed
A network of e-cigarette users in Thailand has urged the new government to review the country’s vape ban, saying official data show that use has risen sharply despite more than a decade of prohibition.
Mar.27 by 2FIRSTS.ai
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
Acting CTP Director Says FDA Cut Premarket Tobacco Application Backlog by About 70% Over the Past Year
FDA Center for Tobacco Products Acting Director Bret Koplow said at the American Tobacco and Nicotine Forum that the agency has reduced its premarket tobacco application backlog by about 70% over the past year and eliminated the acceptance queue. He said FDA has reviewed about 27 million applications, but only a small number have been authorized, mainly because most submissions lacked the scientific data needed to demonstrate public health benefits.
Apr.23 by 2FIRSTS.ai